Related references
Note: Only part of the references are listed.Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
Dhruv S. Kazi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population
Ken Song et al.
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE (2013)
Prevalence of CGG expansions of the FMR1 gene in a US population-based sample
Marsha Mailick Seltzer et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS (2012)
Caregiver opinions about fragile X population screening
Donald B. Bailey et al.
GENETICS IN MEDICINE (2012)
Incidence of Fragile X Syndrome by Newborn Screening for Methylated FMR1 DNA
Bradford Coffee et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2009)
Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years
Anne Andermann et al.
BULLETIN OF THE WORLD HEALTH ORGANIZATION (2008)
Share Paper
